Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF PHASE II CLINICAL TRIAL OF MT200605 FOR ACUTE ISCHEMIC STROKE (AIS) IN CHINA

The board of directors (the "**Board**") of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase II clinical trial (the "**Clinical Trial**") of the Group's independently developed drug candidate MT200605 for the treatment of AIS, has completed. The Clinical Trial has demonstrated significant and robust efficacy advantages with favorable safety profile.

The Clinical Trial is a multi-center, randomized, double-blind and placebo-controlled trial to evaluate the efficacy, safety and pharmacokinetics of MT200605. A total of 360 subjects were enrolled and randomly assigned in a 1:1:1:1 ratio to four groups, including the 10 mg BID group (the "**Low-Dose Group**"), the 20 mg BID group (the "**Medium-Dose Group**"), the 40 mg BID group (the "**High-Dose Group**") and the placebo-controlled group (the "**Placebo Group**"). All four groups received intravenous infusions for 14 consecutive days.

RESULTS OF THE PHASE II CLINICAL TRIAL

Efficacy Results

- The primary efficacy endpoint showed that the proportion of patients achieving a modified Rankin Scale ("**mRS**") score of ≤1 was notably higher in the High-Dose Group than in the Placebo Group, demonstrating a statistically significant difference and clinically meaningful benefit. The mRS score of ≤1 generally indicates no symptoms or no significant disability despite symptoms, with the subject being able to carry out all usual duties and activities.

- The Clinical Trial indicated that the Low-Dose Group, Medium-Dose Group and High-Dose Group demonstrated a clear dose-response relationship.

- The secondary efficacy endpoint results showed that the improvement in National Institutes of Health Stroke Scale ("**NIHSS**") score in the High-Dose Group began to separate from that in the Placebo Group as early as Day 7, with the difference becoming more pronounced by Day 14, suggesting more rapid early neurological recovery among patients in the High-Dose Group.

Safety Results

- MT200605 demonstrated the potential to reduce the incidence of acute kidney injury ("**AKI**") in patients with AIS in a dose-dependent manner. The incidence of AKI in the High-Dose Group was more than 80% lower than that in the Placebo Group, indicating the potential of MT200605 to address an unmet medical need for the prevention of AKI in patients with AIS.

ABOUT AKI

AKI has been reported to occur in approximately 10% to 20% of patients with AIS, with the reported incidence varying depending on the diagnostic criteria, patient populations and clinical settings. According to published literature, approximately 0.15% of patients with AIS require hemodialysis. Among stroke patients with AKI who do not initially require hemodialysis, approximately 28% progress to chronic kidney disease ("**CKD**") during follow-up, with a median time to progression of 40.7 months. AKI is also associated with serious adverse clinical outcomes, including an in-hospital mortality risk approximately two to three times that of patients without AKI, higher rates of moderate-to-severe disability, longer hospital stays and higher inpatient costs, as well as increased long-term mortality and recurrent cardiovascular events.

ABOUT MT200605

To the knowledge of the Company, MT200605 is a first-in-class small-molecule TrkB agonist capable of crossing the blood-brain barrier and targeting the BDNF/TrkB signaling axis, which forms part of the field of neurotrophic factor research pioneered by the work recognized by the 1986 Nobel Prize in Physiology or Medicine. By blocking the ischemic cascade following AIS, MT200605 is designed to protect neural tissues, promote neuronal regeneration and remodeling to facilitate the repair of neurological damage, and relax vascular smooth muscle, thereby potentially improving microcirculation in the ischemic penumbra. MT200605 has the potential to fill the therapeutic gap in the field of neuroprotection and neurological repair for stroke.

In July 2026, the Group announced the completion of database lock for the Clinical Trial. In August 2026, the Group announced that the Clinical Trial had reached its primary endpoint.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 26 August 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.